Takeda Pharmaceutical Company Limited EBIT

As of the most recent data (June 2026), 4502.T shows a EBIT of $650B. That compares with $440B in the prior-year period — up 46.1% year over year. That is above the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4502.T's EBIT is now $650B (was $440B) — a 46.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Takeda Pharmaceutical Company Limited is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Takeda Pharmaceutical Company Limited is at $650B, which is higher that average. That is roughly 2805.3% above the sector mean. Use the comparison chart on this page to see how 4502.T stacks up against individual peers as well.

Tracking 4502.T's ebit over time shows whether Takeda Pharmaceutical Company Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $650B That compares with $440B in the prior-year period — up 46.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Takeda Pharmaceutical Company Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $650B) with ownership activity and broader fundamentals.